Background

US-based biotech company developing phase II product in US/EU, trying to assess whether to expand development activities into Japan now or later.
In planning for an IPO in a few months time, the company needed to ensure that investors understood the true global value of their product.

Objective

Understand Japanese market landscape for a severe, rare disease with only about 3,000 patients. Obtain feedback on product profile for multiple scenarios from KOLs in the pediatrician community in Japan.

Project Summary

• Analyzed market data and projected demand for drugs in the same category.
• Interviewed KOLs regarding opinions and preferences about product profiles. Identified product attribute with competitive advantage.
• Provided comprehensive estimation of NHI price for product developed in rare but debilitating disease space.
  Suggested optimal development strategy for best price to maximize enterprise value of product.
• Proposed local clinical development strategies aligned with global program and meeting local regulatory
  requirements.

Client Feedback

Client was satisfied with our detailed evidence-based work. Our timelines met their need to quickly deliver valuation of their product to the investor community.

Timeline

12 weeks

Key Project Capabilities

• Demand Analysis
• Pricing and Market Access Consultation
• Market Research
• P&L Forecast/Valuation
• Clinical Development Consultation

Deliverables

• Excel-based forecasting model
  Population-based
  Multiple scenarios
  Parametric
  Reflects competitive landscape
  Evidence/fact-based time series analysis using cutting edge algorithms
• PowerPoint presentation
  KOL comments, candid opinions about new product, minimal translation/process loss

Clear optimal development strategy and projection of product incremental value in Japan